What is HC Wainwright's Forecast for Omeros Q1 Earnings?

Key Points

• HC Wainwright analyst B. Folkes forecasts Omeros will report Q1 2026 EPS of ($0.59), keeps a Buy rating and set a $40 price target (up from $20).
• HC Wainwright also models sequential quarterly losses for 2026 (Q2 ($0.61), Q3 ($0.58), Q4 ($0.52)) but projects a long‑term rebound with FY2030 EPS of $6.69, versus the current consensus full‑year loss of ($3.09).
• Market context: OMER trades near $13.45 with a ~$954M market cap and recent volatility, while FDA approval and a disclosed Yartemlea price of $36,000 per vial offer revenue upside but raise payer/access uncertainty that could affect near‑term uptake.

Omeros Corporation (NASDAQ:OMER - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Omeros in a research note issued on Thursday, January 8th. HC Wainwright analyst B. Folkes anticipates that the biopharmaceutical company will earn ($0.59) per share for the quarter. HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros' Q2 2026 earnings at ($0.61) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.52) EPS and FY2030 earnings at $6.69 EPS.

OMER has been the topic of a number of other research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Omeros in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Omeros from a "sell" rating to a "hold" rating in a research note on Saturday, December 13th. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Wednesday, October 15th. D. Boral Capital reaffirmed a "buy" rating and issued a $36.00 price target on shares of Omeros in a research report on Thursday. Finally, WBB Securities reiterated a "strong-buy" rating and set a $45.00 price objective on shares of Omeros in a research note on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Omeros has an average rating of "Moderate Buy" and an average target price of $40.33.

Omeros Stock Down 4.5%

OMER opened at $13.45 on Friday. The stock's fifty day moving average is $10.48 and its two-hundred day moving average is $6.57. The company has a market capitalization of $953.61 million, a P/E ratio of -6.66 and a beta of 2.38. Omeros has a 52 week low of $2.95 and a 52 week high of $17.65.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.39.

Institutional Trading of Omeros

A number of institutional investors have recently modified their holdings of OMER. Russell Investments Group Ltd. raised its stake in shares of Omeros by 113.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 5,677 shares in the last quarter. Trexquant Investment LP acquired a new stake in Omeros in the first quarter valued at approximately $88,000. B. Riley Wealth Advisors Inc. purchased a new position in Omeros in the second quarter worth $32,000. Tower Research Capital LLC TRC increased its position in shares of Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 11,971 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of Omeros during the 2nd quarter valued at $40,000. 48.79% of the stock is currently owned by institutional investors.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: HC Wainwright raised its price target for OMER to $40 (from $20) and carries a Buy rating, signaling analysts see substantial upside versus current levels. This upgrade can support bullish sentiment and buying interest. HC Wainwright raises OMER PT to $40
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating and set a $36 price target, another analyst vote of confidence that could attract momentum buyers. D. Boral reaffirms Buy on OMER
• Positive Sentiment: Omeros showed a post-close/after-hours move higher in recent trading, indicating intraday volatility and that some investors are reacting positively to recent news flows. After-hours strength can sometimes precede renewed buying next session. After-hours move coverage
• Neutral Sentiment: Needham maintained a Hold rating (balanced risk/reward view and gradual ramp for Yartemlea), which tempers the bullish analyst actions and adds a cautious voice to the analyst mix. Needham Hold note
• Neutral Sentiment: Omeros released details on FDA approval and commercialization plans for YARTEMLEA; investors are parsing launch timelines, distribution, and payer strategy — important for revenue visibility but not an immediate binary outcome. FDA approval/commercialization transcript
• Neutral Sentiment: Omeros announced Yartemlea will be priced at $36,000 per single-dose vial. While the price point supports revenue per dose, it also raises potential payer/access questions that could delay uptake — making near-term commercial performance uncertain. Pricing announcement

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.